DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic Applied BioSolutions, Inc. (NASDAQ: DYAI) announced 2Q:26 results on August 12 ...
Complaints are an ordinary part of dealing with people, whether the setting is a shop, a workplace, a technology company or a ...
Phase 1b study will evaluate safety and pharmacokinetics of RSM01 in approximately 80 infants aged 2 weeks to 8 monthsCompany expands its global portfolio beyond vaccines into antibody-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results